Death and inflammation following somatic cell transplantation.

The fields of regenerative medicine and cellular therapy have been the subject of tremendous hype and hope. In particular, the perceived usage of somatic cells like mesenchymal stromal stem cells (MSCs) has captured the imagination of many. Clinical trials are currently evaluating the therapeutic efficacy of MSCs in disorders ranging from heart disease to pediatric graft-vs-host disease; however, numerous questions still remain regarding mechanism of action, effective dose, and whether these cells can be used in the allogeneic setting. One of the major issues surrounding the development of somatic cell therapies like MSCs is that despite evoking a positive response, long-term engraftment and persistence of these cells is rare. Consequently, very large cell doses need be administered raising production, delivery, and efficacy issues. In this review, we will discuss causes for this lack of persistence and highlight some of the methodologies be used to enhance cell survival post-transplantation.